TSHA
Taysha Gene
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
stock price surged significantly
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TSHA
Taysha Gene Therapies, Inc.
A clinical-stage gene therapy company focused on developing treatments for rare genetic diseases
Biological Technology
09/20/2019
09/24/2020
NASDAQ Stock Exchange
73
12-31
Common stock
3000 Pegasus Park Dr. Ste 1430, Dallas, Texas 75247
--
Taysha Gene Therapies, Inc. was originally incorporated under Texas law on September 20, 2019. The Company was converted to a Delaware corporation on February 13, 2020. The Company is a patient-centric gene therapy company dedicated to the development and development of commercialized AAV-based gene therapies for the treatment of rare and large patient populations of central nervous system monogenic diseases.
Company Financials
EPS
TSHA has released its 2024 Q4 earnings. EPS was reported at -0.07, versus the expected -0.09, beating expectations. The chart below visualizes how TSHA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TSHA has released its 2024 Q4 earnings report, with revenue of 2.02M, reflecting a YoY change of -43.90%, and net profit of -18.79M, showing a YoY change of -139.35%. The Sankey diagram below clearly presents TSHA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available